Roth Capital Reduces Earnings Estimates for Sanuwave Health

Key Points

• Roth Capital has lowered its FY2025 EPS estimate for Sanuwave Health from $0.42 to $0.34, while maintaining a "Buy" rating and a price target of $53.00.
• The company reported $0.01 earnings per share in its last quarter, exceeding consensus estimates by $0.10, along with a revenue of $10.16 million.
• Institutional investors hold 42.53% of Sanuwave Health's stock, with several firms recently acquiring new stakes in the company.

Sanuwave Health Inc. (NASDAQ:SNWV - Free Report) - Research analysts at Roth Capital reduced their FY2025 EPS estimates for shares of Sanuwave Health in a research note issued to investors on Monday, October 6th. Roth Capital analyst K. Bauser now anticipates that the company will earn $0.34 per share for the year, down from their previous estimate of $0.42. Roth Capital has a "Buy" rating and a $53.00 price objective on the stock. Roth Capital also issued estimates for Sanuwave Health's Q4 2025 earnings at $0.34 EPS, Q2 2026 earnings at $0.29 EPS, Q3 2026 earnings at $0.41 EPS, Q4 2026 earnings at $0.55 EPS, FY2026 earnings at $1.41 EPS and FY2027 earnings at $2.20 EPS.

Sanuwave Health (NASDAQ:SNWV - Get Free Report) last posted its quarterly earnings data on Friday, August 8th. The company reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.10. The firm had revenue of $10.16 million for the quarter, compared to analyst estimates of $10.14 million. Sanuwave Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS.

Several other brokerages have also issued reports on SNWV. Northland Securities began coverage on shares of Sanuwave Health in a research note on Wednesday, September 3rd. They set an "outperform" rating and a $55.00 target price on the stock. Northland Capmk raised shares of Sanuwave Health to a "strong-buy" rating in a research note on Wednesday, September 3rd. Weiss Ratings reissued a "sell (d-)" rating on shares of Sanuwave Health in a research note on Wednesday. Finally, Wall Street Zen raised shares of Sanuwave Health from a "hold" rating to a "buy" rating in a research note on Friday, October 3rd. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Sanuwave Health presently has a consensus rating of "Moderate Buy" and a consensus price target of $54.00.

Sanuwave Health Stock Down 2.1%

SNWV opened at $31.33 on Thursday. Sanuwave Health has a twelve month low of $5.63 and a twelve month high of $46.58. The company has a fifty day moving average of $37.69 and a 200-day moving average of $33.86. The stock has a market cap of $268.44 million, a PE ratio of -3.80 and a beta of 1.33.

Institutional Trading of Sanuwave Health

Institutional investors and hedge funds have recently made changes to their positions in the company. Goldman Sachs Group Inc. purchased a new stake in shares of Sanuwave Health in the first quarter valued at about $337,000. Solas Capital Management LLC purchased a new stake in shares of Sanuwave Health in the first quarter valued at about $20,658,000. Strategic Investment Solutions Inc. IL purchased a new stake in shares of Sanuwave Health in the first quarter valued at about $47,000. AWM Investment Company Inc. purchased a new stake in shares of Sanuwave Health in the first quarter valued at about $18,153,000. Finally, Rhumbline Advisers purchased a new stake in shares of Sanuwave Health in the second quarter valued at about $211,000. Hedge funds and other institutional investors own 42.53% of the company's stock.

About Sanuwave Health

SANUWAVE Health, Inc, a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.